JP5737949B2 - 薬物制御送達用の非ポリマー組成物 - Google Patents

薬物制御送達用の非ポリマー組成物 Download PDF

Info

Publication number
JP5737949B2
JP5737949B2 JP2010545996A JP2010545996A JP5737949B2 JP 5737949 B2 JP5737949 B2 JP 5737949B2 JP 2010545996 A JP2010545996 A JP 2010545996A JP 2010545996 A JP2010545996 A JP 2010545996A JP 5737949 B2 JP5737949 B2 JP 5737949B2
Authority
JP
Japan
Prior art keywords
composition
acid
hormone
group
factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010545996A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011511088A (ja
JP2011511088A5 (enExample
Inventor
ユーフア リー
ユーフア リー
アンドリュー ガリーノ
アンドリュー ガリーノ
ベンジャミン チエン
ベンジャミン チエン
Original Assignee
キューピーエス リミテッド ライアビリティ カンパニー
キューピーエス リミテッド ライアビリティ カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by キューピーエス リミテッド ライアビリティ カンパニー, キューピーエス リミテッド ライアビリティ カンパニー filed Critical キューピーエス リミテッド ライアビリティ カンパニー
Publication of JP2011511088A publication Critical patent/JP2011511088A/ja
Publication of JP2011511088A5 publication Critical patent/JP2011511088A5/ja
Application granted granted Critical
Publication of JP5737949B2 publication Critical patent/JP5737949B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2010545996A 2008-02-08 2009-02-05 薬物制御送達用の非ポリマー組成物 Expired - Fee Related JP5737949B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6517808P 2008-02-08 2008-02-08
US61/065,178 2008-02-08
PCT/US2009/033226 WO2009100222A1 (en) 2008-02-08 2009-02-05 Non-polymeric compositions for controlled drug delivery

Publications (3)

Publication Number Publication Date
JP2011511088A JP2011511088A (ja) 2011-04-07
JP2011511088A5 JP2011511088A5 (enExample) 2014-01-09
JP5737949B2 true JP5737949B2 (ja) 2015-06-17

Family

ID=40952458

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010545996A Expired - Fee Related JP5737949B2 (ja) 2008-02-08 2009-02-05 薬物制御送達用の非ポリマー組成物

Country Status (8)

Country Link
US (1) US8586103B2 (enExample)
EP (1) EP2244679A4 (enExample)
JP (1) JP5737949B2 (enExample)
CN (1) CN102131483A (enExample)
AU (1) AU2009212373B2 (enExample)
CA (1) CA2714514C (enExample)
TW (1) TWI400090B (enExample)
WO (1) WO2009100222A1 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
CN101677952B (zh) 2007-05-18 2012-12-05 杜雷科特公司 改进的贮库制剂
EP2152315B1 (en) 2007-05-25 2016-01-06 Indivior UK Limited Sustained delivery formulations of risperidone compounds
EP2254559B1 (en) * 2008-02-08 2018-10-10 Foresee Pharmaceuticals Co., Ltd. Composition for sustained release delivery of proteins or peptides
US9498440B2 (en) 2009-05-22 2016-11-22 Inventia Healthcare Private Limited Extended release pharmaceutical compositions
IE20100174A1 (en) * 2010-03-25 2012-02-29 Trinity College Dublin Transdermal administration of peptides
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US11998516B2 (en) 2011-03-07 2024-06-04 Tonix Pharma Holdings Limited Methods and compositions for treating depression using cyclobenzaprine
KR101494594B1 (ko) 2011-08-30 2015-02-23 주식회사 종근당 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
CN102961362B (zh) * 2012-12-03 2014-07-30 上海应用技术学院 一种β-聚苹果酸/壳聚糖纳米药物缓释微胶囊及其制备方法
KR101586789B1 (ko) * 2012-12-28 2016-01-19 주식회사 종근당 양이온성 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
KR101586791B1 (ko) 2012-12-28 2016-01-19 주식회사 종근당 ＧｎＲＨ 유도체의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
WO2014164754A1 (en) 2013-03-11 2014-10-09 Durect Corporation Injectable controlled release composition comprising high viscosity liquid carrier
US20140308352A1 (en) 2013-03-11 2014-10-16 Zogenix Inc. Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material
MY196014A (en) 2013-03-15 2023-03-06 Tonix Pharmaceuticals Inc Eutectic Formulations of Cyclobenzaprine Hydrochloride and Amitriptyline Hydrochloride
WO2015088990A1 (en) 2013-12-09 2015-06-18 Durect Corporation Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
KR20170054459A (ko) 2014-09-10 2017-05-17 더블 본드 파마슈티컬스 에이비 친수성 약물의 표적 전달 방법
WO2016046673A1 (en) * 2014-09-28 2016-03-31 Mohan M Alapati Compositions and methods for the treatment of neurological diseases
CN104721809A (zh) * 2015-03-12 2015-06-24 内蒙古金河动物药业有限公司 一种包含硫酸黏菌素的药物组合物及其制备方法
WO2016205701A1 (en) 2015-06-19 2016-12-22 University Of Southern California Enteral fast access tract platform system
US10631564B2 (en) 2015-06-19 2020-04-28 University Of Southern California Enterically coated microparticle compositions and methods for modified nutrient delivery
CN105727260A (zh) * 2016-02-03 2016-07-06 华侨大学 一种卵泡刺激素的长效制剂
EP3426228A1 (en) * 2016-03-07 2019-01-16 Double Bond Pharmaceutical AB Targeted delivery of hydrophilic drugs to lung
US10682340B2 (en) * 2016-06-30 2020-06-16 Durect Corporation Depot formulations
CN109310680B (zh) * 2016-06-30 2022-11-01 度瑞公司 长效配制物
EA201990127A1 (ru) * 2016-12-30 2020-08-18 Дьюрект Корпорейшн Депо-препарат
CN107173664A (zh) * 2017-04-27 2017-09-19 南昌大学 一种提高乳状液稳定性的没食子酸月桂酯复合抗氧化剂
BR112020011345A2 (pt) 2017-12-11 2020-11-17 Tonix Pharma Holdings Limited tratamento com ciclobenzaprina para agitação, psicose e declínio cognitivo na demência e condições neurodegenerativas
EP3620494A1 (en) 2018-09-06 2020-03-11 Holland Novochem Technical Coatings B.V. Rheology modifier and compatibilizer
CN111388406B (zh) * 2020-03-24 2024-02-23 西安力邦医药科技有限责任公司 氟维司群或其衍生物可注射递药贮库及其制备方法和应用
ES3038506T3 (en) * 2020-05-20 2025-10-13 Medrx Co Ltd Apomorphine-containing percutaneous absorption type preparation
CN113368041B (zh) * 2020-07-17 2023-01-03 丽珠医药集团股份有限公司 药物组合物、缓释制剂及其制备方法
CN112806359B (zh) * 2020-12-30 2022-03-11 河北威远生物化工有限公司 一种生物可降解型农药缓释乳油及其制备方法和应用
CN116744974A (zh) * 2021-01-01 2023-09-12 普渡研究基金会 用于吸入的多黏菌素的共制剂
CN115068414B (zh) * 2021-03-16 2023-07-21 湖南慧泽生物医药科技有限公司 供注射用罗哌卡因长效溶液制剂及其制备方法
EP4282435A1 (en) * 2022-05-23 2023-11-29 Danmarks Tekniske Universitet Formulations of active pharmaceutical ingredients and excipients in icells via hydrophobic ion pairing
CN116421578A (zh) * 2023-03-31 2023-07-14 辉粒药业(苏州)有限公司 生长抑素类似物缓释微球及其制备方法
WO2025235457A1 (en) 2024-05-09 2025-11-13 Alsteni Medical, Inc. Intraoral gastrointestinal access device and related methods
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3932610A (en) * 1971-12-06 1976-01-13 Lever Brothers Company Shampoo composition
WO1994008599A1 (en) * 1992-10-14 1994-04-28 The Regents Of The University Of Colorado Ion-pairing of drugs for improved efficacy and delivery
US5747058A (en) 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
US5968542A (en) 1995-06-07 1999-10-19 Southern Biosystems, Inc. High viscosity liquid controlled delivery system as a device
EP1525858A1 (en) * 1995-06-07 2005-04-27 Durect Corporation High viscosity liquid controlled delivery system
US6413536B1 (en) 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
JPH10218745A (ja) * 1997-02-12 1998-08-18 Rashieru Seiyaku Kk シャンプー組成物
US6051558A (en) 1997-05-28 2000-04-18 Southern Biosystems, Inc. Compositions suitable for controlled release of the hormone GnRH and its analogs
CA2324254C (en) * 1998-03-18 2005-01-04 University Technology Corporation Sustained-release composition including amorphous polymer
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
JP4361710B2 (ja) * 2000-04-19 2009-11-11 ジェネンテック・インコーポレーテッド 徐放製剤
DE10312346A1 (de) * 2003-03-20 2004-09-30 Bayer Healthcare Ag Kontrolliertes Freisetzungssystem
AU2004259208B2 (en) * 2003-07-15 2011-04-28 Evonik Corporation Method for the preparation of controlled release formulations
DK2767292T3 (en) * 2004-09-17 2016-12-19 Durect Corp RENEWABLE local anesthetic COMPOSITION CONTAINING SAIB

Also Published As

Publication number Publication date
EP2244679A1 (en) 2010-11-03
CN102131483A (zh) 2011-07-20
US20100034801A1 (en) 2010-02-11
AU2009212373A2 (en) 2011-02-17
WO2009100222A1 (en) 2009-08-13
CA2714514A1 (en) 2009-08-13
CA2714514C (en) 2016-08-16
EP2244679A4 (en) 2013-10-09
JP2011511088A (ja) 2011-04-07
TWI400090B (zh) 2013-07-01
US8586103B2 (en) 2013-11-19
TW200936167A (en) 2009-09-01
AU2009212373A1 (en) 2009-08-13
AU2009212373B2 (en) 2013-10-03

Similar Documents

Publication Publication Date Title
CA2714514C (en) Non-polymeric compositions for controlled drug delivery
US10646572B2 (en) Pharmaceutical compositions with enhanced stability
JP5718058B2 (ja) タンパク質又はペプチドの徐放送達用組成物
JP2011511088A5 (enExample)
AU2005271242B9 (en) Pharmaceutical compositions for controlled release delivery of biologically active compounds
CA2657911C (en) Pharmaceutical compositions for sustained release delivery of peptides
KR20210005542A (ko) 선택된 방출 기간을 갖는 약제학적 조성물
HK1162295A (en) Non-polymeric compositions for controlled drug delivery

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120206

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20120206

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130814

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20130816

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20131114

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140310

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140610

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20141014

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150216

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20150313

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150413

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150421

R150 Certificate of patent or registration of utility model

Ref document number: 5737949

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees